LBPS实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (1 Jan 1970 @ 08:00):

Stats
今日成交量	3 914.00
平均成交量	11 314.00
市值	0.00
EPS	$0 ( 2022-03-31 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.220 (13.33%)

音量相关性

長: 0.32 (neutral)

短: -0.32 (neutral)

Signal:(22.657) Neutral

4D pharma plc 相关性

10 最正相关
UTHR	0.931
GOOD	0.925
ALXO	0.917
HALO	0.917
BEAT	0.917
BCYC	0.916
CBNK	0.915
PSHG	0.914
EAR	0.91
IBRX	0.908

10 最负相关
DAKT	-0.934
AXON	-0.914
DUOL	-0.912
LMNR	-0.908
DAIO	-0.901
OSPN	-0.901
BWMX	-0.9
ALTR	-0.899
OMAB	-0.897
ANSS	-0.897

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

4D pharma plc 相关性 - 货币/商品

-0.47
( neutral )

-0.54
( weak negative )

0.18
( neutral )

-0.27
( neutral )

0.18
( neutral )

0.07
( neutral )

4D pharma plc 财务报表

Annual	2021
营收:	$718 000
毛利润:	$0.00 (0.00 %)
EPS:	$-1.520

FY	2021
营收:	$718 000
毛利润:	$0.00 (0.00 %)
EPS:	$-1.520

FY	2020
营收:	$534 000
毛利润:	$0.00 (0.00 %)
EPS:	$-1.824

FY	2019
营收:	$211 000
毛利润:	$0.00 (0.00 %)
EPS:	$-2.94

Financial Reports:

No articles found.

4D pharma plc

4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom. The company develops therapeutic candidates, including MRx0518 for the treatment of cancer and immune-oncology diseases; MRx-4DP0004 for the treatment of asthma; MRx0029 and MRx0005 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, such as MRx1299 for solid tumors, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. In addition, the company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate MRx0518; strategic collaboration agreement with University of Texas MD Anderson for discovery and development of LBPs in oncology; and Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda, MRx0518 in patients with solid tumors, and to discover and develop LBPs for vaccines. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.